ABSTRACT
There is now compelling evidence that the tumour stroma plays an important role in the pathogenesis of cancers of epithelial origin. The pre-eminent cell type of the stroma is carcinoma-associated fibroblasts. These cells demonstrate remarkable heterogeneity with activation and senescence being common stress responses. In this review, we summarise the part that these cells play in cancer, particularly oral cancer, and present evidence to show that activation and senescence reflect a unified programme of fibroblast differentiation. We report advances concerning the senescent fibroblast metabolome, mechanisms of gene regulation in these cells and ways in which epithelial cell adhesion is dysregulated by the fibroblast secretome. We suggest that the identification of fibroblast stress responses may be a valuable diagnostic tool in the determination of tumour behaviour and patient outcome. Further, the fact that stromal fibroblasts are a genetically stable diploid cell population suggests that they may be ideal therapeutic targets and early work in this context is encouraging.
Subject(s)
Fibroblasts/physiology , Mouth Neoplasms/pathology , Cellular Senescence , Fibroblasts/cytology , Fibroblasts/metabolism , Humans , Metabolome , Mouth Neoplasms/metabolism , Mouth Neoplasms/physiopathologyABSTRACT
NOTCH signalling can exert oncogenic or tumour suppressive effects in both solid and haematological malignancies. Similar to T-cell acute lymphoblastic leukaemia (T-ALL), early studies suggested a pro-tumorigenic role of NOTCH in head and neck squamous cell carcinoma (HNSCC), mainly based on the increased expression levels of the genes within the pathway. Recently, data from exome sequencing analyses unexpectedly pointed to a tumour suppressor role for NOTCH in HNSCC by identifying loss-of-function mutations in the NOTCH1 gene in a significant proportion of patients. These data have questioned the accepted role of NOTCH in HNSCC and the possible rationale of targeting NOTCH in this disease. This review summarises the current information on NOTCH signalling in HNSCC and discusses how this pathway can apparently exert opposing effects within the same disease.
Subject(s)
Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/metabolism , Receptors, Notch/genetics , Receptors, Notch/metabolism , Signal Transduction , Animals , Genes, Tumor Suppressor , Humans , Mutation , Signal Transduction/geneticsABSTRACT
Lysophosphatidic acid (LPA), a pleiotropic signalling lipid is assuming growing significance in osteoblast biology. Although committed osteoblasts from several mammalian species are receptive to LPA far less is known about the potential for LPA to influence osteoblast formation from their mesenchymal progenitors. An essential factor for both bone development and post-natal bone growth and homeostasis is the active metabolite of vitamin D3, calcitriol (D3). Previously we reported how a combination of LPA and D3 synergistically co-operated to enhance the differentiation of immature human osteoblasts. Herein we provide evidence for the formation of human osteoblasts from multiple, primary human bone marrow derived stromal (stem) cells (hBMSCs). Importantly osteoblast development from hBMSCs only occurred when LPA was administered as a complex with albumin, its natural carrier. Collectively our findings support a co-operative role of LPA and D3 in osteoblastogenesis, findings which may aid the development of novel treatment strategies for bone repair.
Subject(s)
Adult Stem Cells/drug effects , Bone Marrow Cells/drug effects , Calcitriol/pharmacology , Cell Differentiation/drug effects , Lysophospholipids/pharmacology , Osteoblasts/cytology , Serum Albumin , Adult Stem Cells/cytology , Aged , Alkaline Phosphatase/chemistry , Alkaline Phosphatase/metabolism , Bone Marrow Cells/cytology , Bone Regeneration/drug effects , Cell Proliferation , Cells, Cultured , Cholecalciferol/pharmacology , Drug Carriers , Enzyme Assays , Female , Gene Expression , Humans , Male , Middle Aged , Receptors, Lysophosphatidic Acid/genetics , Receptors, Lysophosphatidic Acid/metabolismABSTRACT
Oral squamous cell carcinoma (OSCC) is a lethal disease and early death usually occurs as a result of local invasion and regional lymph node metastases. Current treatment regimens are, to a certain degree, inadequate, with a 5-year mortality rate of around 50% and novel therapeutic targets are urgently required. Using expression microarrays, we identified the eps8 gene as being overexpressed in OSCC cell lines relative to normal oral keratinocytes, and confirmed these findings using RT-PCR and western blotting. In human tissues, we found that Eps8 was upregulated in OSCC (32% of primary tumors) compared with normal oral mucosa, and that expression correlated significantly with lymph node metastasis (P=0.032), suggesting a disease-promoting effect. Using OSCC cell lines, we assessed the functional role of Eps8 in tumor cells. Although suppression of Eps8 produced no effect on cell proliferation, both cell spreading and migration were markedly inhibited. The latter cell functions may be modulated through the small GTP-ase, Rac1 and we used pull-down assays to investigate the role of Eps8 in Rac1 signaling. We found that alphavbeta6- and alpha5beta1-integrin-dependent activation of Rac1 was mediated through Eps8. Knockdown of either Eps8 or Rac1, inhibited integrin-dependent cell migration similarly and transient expression of constitutively active Rac1 restored migration of cells in which Eps8 expression had been suppressed. We also showed that knockdown of Eps8 inhibited tumor cell invasion in an organotypic model of OSCC. These data suggest that Eps8 and Rac1 are part of an integrated signaling pathway modulating integrin-dependent tumour cell motility and identify Eps8 as a possible therapeutic target.
Subject(s)
Carcinoma, Squamous Cell/pathology , Cell Movement , Integrins/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Mouth Neoplasms/pathology , rac1 GTP-Binding Protein/metabolism , Adaptor Proteins, Signal Transducing , Antigens, Neoplasm/metabolism , Blotting, Western , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Cell Line, Tumor , Cell Membrane/metabolism , Cells, Cultured , Flow Cytometry , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , Intracellular Signaling Peptides and Proteins/genetics , Keratinocytes/cytology , Keratinocytes/metabolism , Mouth Mucosa/cytology , Mouth Mucosa/metabolism , Mouth Neoplasms/genetics , Mouth Neoplasms/metabolism , Neoplasm Invasiveness , Oligonucleotide Array Sequence Analysis , RNA Interference , Receptors, Vitronectin/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation , rac1 GTP-Binding Protein/geneticsABSTRACT
The transforming growth factor-beta (TGF-beta) family of cytokines consists of multi-functional polypeptides that regulate a variety of cell processes, including proliferation, differentiation, apoptosis, extracellular matrix elaboration, angiogenesis, and immune suppression, among others. In so doing, TGF-beta plays a key role in the control of cell behavior in both health and disease. In this report, we review what is known about the mechanisms of activation of the peptide, together with details of TGF-beta signal transduction pathways. This review summarizes the evidence implicating TGF-beta in normal physiological processes of the craniofacial complex-such as palatogenesis, tooth formation, wound healing, and scarring-and then evaluates its role in non-malignant disease processes such as scleroderma, submucous fibrosis, periodontal disease, and lichen planus.
Subject(s)
Signal Transduction/physiology , Transforming Growth Factor beta/physiology , Animals , DNA-Binding Proteins/metabolism , Humans , Mouth Diseases/metabolism , Odontogenesis/physiology , Palate, Hard/embryology , Smad Proteins , Trans-Activators/metabolismABSTRACT
The role of transforming growth factor-beta (TGF-beta) in epithelial malignancy is complex, but it is becoming clear that, in the early stages of carcinogenesis, the protein acts as a potent tumor suppressor, while later, TGF-beta can function to advance tumor progression. We review the evidence to show that the pro-oncogenic functions of TGF-beta are associated with (1) a partial loss of response to the ligand, (2) defects of components of the TGF-beta signal transduction pathway, (3) over-expression and/or activation of the latent complex, (4) epithelial-mesenchymal transition, and (5) recruitment of signaling pathways which act in concert with TGF-beta to facilitate the metastatic phenotype. These changes are viewed in the context of what is known about the pathogenesis of oral cancer and whether this knowledge can be translated into the development of new therapeutic modalities.
Subject(s)
Carcinoma/metabolism , Mouth Neoplasms/metabolism , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/physiology , Animals , Carcinoma/genetics , Cell Transformation, Neoplastic , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Epithelial Cells/pathology , Gene Expression Regulation, Neoplastic , Humans , Mouth Neoplasms/genetics , Neoplasm Metastasis/genetics , Signal Transduction/physiology , Smad Proteins , Trans-Activators/genetics , Trans-Activators/metabolismABSTRACT
This study examined the behaviour of nine human malignant oral keratinocyte cell lines following orthotopic transplantation to the floor of the mouth of athymic mice. Tumourigenesis, local spread, and metastatic dissemination were correlated with known cellular responses to transforming growth factor-beta 1 (TGF-beta 1). Six of nine cell lines were tumourigenic; four of these cell lines showed local spread which was characterized by vascular and bone invasion. Metastatic spread was uncommon, with only 9% of animals with primary tumours developing metastases and these were almost exclusively found in the regional lymph nodes; there was one pulmonary metastasis and no liver deposits. Tumour cell behaviour did not reflect the clinical stage of the original tumours. Cell lines that were resistant to TGF-beta 1-induced growth inhibition were more likely to form primary tumours, exhibit local spread, and metastasize than cells that were growth-inhibited by the ligand. The data demonstrate that tumourigenicity and tumour behaviour in this orthotopic mouse model varied between cell lines and that the pattern of local invasion and metastasis was similar to that seen in human oral cancer. Furthermore, cell lines that were refractory to the growth inhibitory effects of TGF-beta 1 behaved more aggressively than cells that underwent ligand-induced cell-cycle arrest.
Subject(s)
Carcinoma, Squamous Cell/secondary , Keratinocytes/transplantation , Mouth Neoplasms/pathology , Transforming Growth Factor beta/pharmacology , Adult , Aged , Aged, 80 and over , Animals , Carcinoma, Squamous Cell/pathology , Cell Division/drug effects , Cell Line, Tumor , Female , Humans , Lymphatic Metastasis , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Middle Aged , Neoplasm Transplantation , Phenotype , Transforming Growth Factor beta1 , Transplantation, HeterologousABSTRACT
This study examined the expression of MMP-2 and MMP-9 in normal and human malignant oral keratinocytes. The expression of pro-MMP-2 and pro-MMP-9 was heterogeneous in the malignant cell lines. Normal oral keratinocytes expressed less pro-MMP-2 and more pro-MMP-9 than their malignant counterparts. Cells that expressed high levels of both MMP-2 and MMP-9 showed the greatest degree of invasion through Matrigel in vitro compared to cells with either low or variable levels of these enzymes; normal keratinocytes were non-invasive in these conditions. The degree to which the cells invaded through Matrigel was similar to their motility in the absence of Matrigel and was not influenced by the activation of the pro-enzymes or the inhibition of enzyme activity using a chemical inhibitor of gelatinases. Cells were transplanted orthotopically to athymic mice and demonstrated a variable capacity not only to form tumours at the site of inoculation but, also, to metastasise; normal oral keratinocytes were non-tumorigenic. There was no correlation between the expression of either MMP-2 or MMP-9 and the tumorigenic/metastatic phenotype. The results emphasise the limitations of correlating in vitro and in vivo assays of tumour cell behaviour and suggest that invasion/motility in vitro may be a distinct phenotype from tumorigenicity/metastasis in vivo.
Subject(s)
Carcinoma, Squamous Cell/enzymology , Keratinocytes/enzymology , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Mouth Neoplasms/enzymology , Adult , Aged , Aged, 80 and over , Animals , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/secondary , Cell Movement , Female , Humans , Male , Mice , Mice, Inbred BALB C , Middle Aged , Mouth Neoplasms/pathology , Neoplasm Invasiveness , Neoplasm Transplantation , Transplantation, Heterologous , Tumor Cells, CulturedABSTRACT
The underlying principles of homeopathy include treating 'like with like' by remedies which are potentized by serial dilution and succussion. These distinguish homeopathy from other forms of alternative or complementary therapy. Conventional scientific wisdom dictates that homeopathy should have no effect above and beyond placebo but experiments on ultra-high dilutions of solutes together with some clinical data suggest the intriguing possibility that it might do in some circumstances. However, most clinical evidence comes from treating relatively minor self-limiting diseases and little comes from treating life-threatening disorders such as cancer. This paper explains the principles of homeopathy and reviews the data on its use in cancer care.
Subject(s)
Homeopathy , Neoplasms/therapy , HumansABSTRACT
There is increasing evidence that, for many cancers, the survival of socioeconomically deprived patients is worse compared with those who are more affluent. This study provides additional evidence that this is true for patients with head and neck cancers. However, the detrimental effects of deprivation were not found to be lifelong, and in this study, were confined to the first 12-18 months after diagnosis. After this there were no significant deprivation-associated effects on subsequent survival. The reasons for the initial increased mortality in the deprived are not clear but may be related to more advanced stage, more biologically aggressive cancers, greater co-morbidity or worse treatment.
Subject(s)
Carcinoma, Squamous Cell/economics , Carcinoma, Squamous Cell/mortality , Head and Neck Neoplasms/economics , Head and Neck Neoplasms/mortality , Registries , Social Class , Adolescent , Adult , Aged , Child , Child, Preschool , Databases, Factual , England/epidemiology , Female , Health Services Accessibility , Humans , Infant , Infant, Newborn , Male , Middle Aged , Morbidity , Prognosis , Survival , Wales/epidemiologySubject(s)
Informed Consent , Neoplasms/epidemiology , Registries/standards , Government Agencies , Humans , Research Subjects , United KingdomABSTRACT
Several studies have suggested that melanomas may be significantly under-recorded in cancer registries and that smaller, thinner, better prognosis lesions are the ones most likely to be missed. A systematic search of three independent sources of melanoma data in Wales for 1998 revealed a total of 406 histologically confirmed cases, of which only 194 were known to the cancer registry. Eighty-one per cent of the total cases were registered on a specialist melanoma register, compared with 48% on the cancer registry database. From the cancer registry data alone, the world age-standardized incidence rates (WASRs) were 4.3 and 5.8 per 100,000 for males and females, respectively, but these increased to 8.2 and 10.2 with the addition of histologically confirmed cases discovered from other sources. The capture-recapture method estimated the number of melanomas not ascertained by either means to be 140, resulting in a 'true' incidence of 546 cases for 1998 compared with just 194 cases from the cancer registry data alone. The 'true' WASRs are 11.2 and 13.4 per 100,000 for males and females, respectively, which are some of the highest in Europe. There was evidence to support the hypothesis that smaller, thinner melanomas are more likely to be recorded on a specialist melanoma register than on the cancer registry database.
Subject(s)
Melanoma/diagnosis , Melanoma/epidemiology , Databases, Factual , Female , Humans , Male , Models, Statistical , Models, Theoretical , WalesABSTRACT
Our study examined the expression of AP-1 family members in keratinocytes derived from the rat-4NQO model of oral carcinogenesis in which extremes of epithelial differentiation and tumour cell aggressiveness are evident. The constitutive expression of JunB was diminished in the undifferentiated, more aggressive tumour phenotype compared with the well-differentiated, less aggressive keratinocytes, whereas the expression of other AP-1 family members (c-jun, junD, c-fos, fra1, fra2 and fosB) was either very weak or variable. After transfection of the undifferentiated keratinocytes with junB cDNA, clonal populations were isolated that expressed similar levels of JunB protein as the well-differentiated cells. Both untransfected and transfected cell lines were keratin negative and vimentin positive. Increased expression of JunB in the transfected cells resulted in up-regulation of c-Jun and Fra1 and an enhanced AP-1 activity as demonstrated by transcriptional activation of the prototypic AP-1 dependent promoter, MMP-1. JunB transfected cells grew more quickly than vector-only controls and were refractory to the growth inhibitory effects of TGF-beta1. Over-expression of JunB resulted in the elevated expression of the AP-1 dependent proteinase, MMP-9, whereas the expression of the AP-1 independent enzyme, MMP-2, was unaffected. JunB transfected keratinocytes were highly invasive in an in vitro assay of tumour cell invasion compared with vector controls. The results indicate that increased expression of JunB above baseline levels in undifferentiated rat keratinocytes does not alter epithelial differentiation but enhances the malignant phenotype in vitro, possibly by altering the dynamics of the AP-1 complex.
Subject(s)
Keratinocytes/metabolism , Mouth Neoplasms/metabolism , Proto-Oncogene Proteins c-jun/biosynthesis , 3T3 Cells , 4-Nitroquinoline-1-oxide , Animals , Bacterial Proteins/biosynthesis , Blotting, Northern , Blotting, Western , Carcinogens , Cell Differentiation , Cell Division , Cell Movement , Cells, Cultured , DNA, Complementary/metabolism , DNA-Binding Proteins/biosynthesis , Fos-Related Antigen-2 , Genes, Reporter , Genetic Vectors , Keratins/biosynthesis , Luciferases/metabolism , Matrix Metalloproteinase 2/biosynthesis , Matrix Metalloproteinase 9/biosynthesis , Mice , Neoplasms, Experimental/chemically induced , Phenotype , Plasmids/metabolism , Promoter Regions, Genetic , Proto-Oncogene Proteins c-fos/biosynthesis , Rats , Time Factors , Transcription Factor AP-1/biosynthesis , Transcription Factors/biosynthesis , Transcriptional Activation , Transfection , Transforming Growth Factor beta/metabolism , Transforming Growth Factor beta1 , Tumor Cells, Cultured , Up-Regulation , Vimentin/biosynthesisABSTRACT
TGF-beta is a ubiquitous protein that exhibits a broad spectrum of biological activity. The prokaryotic expression and purification of the extracellular domain of the type II TGF-beta receptor (T beta R-II-ED), without the need for fusion protein cleavage and refolding, is described. The recombinant T beta R-II-ED fusion protein bound commercially available TGF-beta 1 and displayed an affinity of 11.1 nM. In a modified ELISA, receptor binding to TGF-beta1 was inhibited by TGF-beta 3. The technique lends itself to high-throughput screening of combinatorial libraries for the identification of TGF-beta agonists and antagonists and this, in turn, may have important therapeutic implications.
Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , Receptors, Transforming Growth Factor beta/biosynthesis , Transforming Growth Factor beta/chemistry , Binding, Competitive , Humans , Kinetics , Polymerase Chain Reaction/methods , Protein Serine-Threonine Kinases , Protein Structure, Tertiary , Receptor, Transforming Growth Factor-beta Type II , Receptors, Transforming Growth Factor beta/agonists , Receptors, Transforming Growth Factor beta/antagonists & inhibitors , Receptors, Transforming Growth Factor beta/chemistry , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Transforming Growth Factor beta/pharmacology , Transforming Growth Factor beta1 , Transforming Growth Factor beta3ABSTRACT
This study examined the immunocytochemical expression of the transforming growth factor-beta (TGF-beta) isoforms TGF-beta1, TGF-beta2, and TGF-beta3, together with the TGF-beta cell surface receptors TbetaR-I and TbetaR-II, in patient-matched tissue pairs of normal human oral epithelium, primary squamous cell carcinomas, and metastatic lymph node tumour deposits. There were no significant differences in the intensity of TGF-beta isoform specific staining between the normal oral epithelium, the primary tumours, and the lymph node metastases. By contrast, there was significantly less TbetaR-II in the metastases than in the primary tumour and between the primary tumour and the normal oral epithelium. Similar trends were evident with TbetaR-I, but not at a statistically significant level. This study also examined the structure of TbetaR-I and TbetaR-II in normal human oral keratinocytes in vitro and in 14 human oral carcinoma cell lines with known responses to TGF-beta1. No structural abnormalities of TbetaR-II were present in the normal keratinocytes or in 13 of 14 malignant cell lines; in one line, there were both normal and mutant forms of TbetaR-II, the latter being in the form of a frameshift mutation with the insertion of a single adenine base (bases 709-718, codons 125-128), predicting a truncated receptor having no kinase domain. No defects were present in TbetaR-I. The structures of TbetaR-I and TbetaR-II did not correlate with growth inhibition by TGF-beta1. The data suggest that decreased expression of TGF-beta receptors, rather than structural defects of these genes, may be important in oral epithelial tumour progression. In order to examine the functional significance of a specific decrease in TbetaR-II expression, a dominant-negative TbetaR-II construct (dnTbetaR-II) was transfected into a human oral carcinoma cell line with a normal TGF-beta receptor profile and known to be markedly inhibited by TGF-beta1. In those clones that overexpressed the dnTbetaR-II, growth inhibition and Smad binding activity were decreased, whilst the regulation of Fra-1 and collagenase-1 remained unchanged following treatment with TGF-beta1. The results demonstrate that a decrease in TbetaR-II relative to TbetaR-I leads to selective gene regulation with loss of growth inhibition but continued transcription of AP-1-dependent genes that are involved in the regulation of the extracellular matrix.
Subject(s)
Carcinoma, Squamous Cell/metabolism , Mouth Neoplasms/metabolism , Receptors, Transforming Growth Factor beta/metabolism , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/secondary , Disease Progression , Female , Humans , Immunoenzyme Techniques , Lymphatic Metastasis , Male , Middle Aged , Mutation , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Protein Isoforms/metabolism , Receptors, Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/metabolism , Tumor Cells, CulturedABSTRACT
This paper examines the genetic defects associated with inherited cancer syndromes and their relevance to oral cancer. Tumour suppressor genes are now thought of as either gatekeepers or caretakers according to whether they control cell growth directly by inhibiting cell proliferation and/or promoting cell death (gatekeepers) or whether they maintain the integrity of the genome by DNA repair mechanisms (caretakers). In disorders such as xeroderma pigmentosum, ataxia telangiectasia, Bloom syndrome and Fanconi's anaemia, where there are defective caretaker genes, there is an increased incidence of second primary malignancies, including oral cancer. By contrast, with the exception of Li Fraumeni syndrome, abnormalities of gatekeeper genes do not predispose to oral cancer. Not only do Li Fraumeni patients develop second primary malignancies, but defects of the p53 pathway (p53 mutation, MDM2 over-expression, CDKN2A deletion) appear to be a ubiquitous feature of sporadic oral cancer as it occurs in the West. The findings suggest that genetic instability is of fundamental importance in the pathogenesis of oral cancer.
Subject(s)
Carcinoma, Squamous Cell/genetics , Mouth Neoplasms/genetics , Neoplastic Syndromes, Hereditary/genetics , Genes, Suppressor , Genetic Predisposition to Disease , Humans , Neoplastic Syndromes, Hereditary/classification , Proto-OncogenesABSTRACT
This study examined the effect of stable transfection of latent transforming growth factor-beta1 (TGF-beta1) cDNA into a predominantly polygonal, 4 nitroquinoline N-oxide (4NQO)-induced rat oral keratinocyte cell line. Seven polygonal and five spindle clonal populations were isolated that overexpressed TGF-beta1 protein by approximately two- to four-fold compared to vector-only transfected controls. Neutralisation experiments indicated that the majority of protein was in the latent form. There was no change in the proportion of polygonal and spindle cells in vitro after transfection with TGF-beta1 cDNA. Polygonal and spindle cells that overexpressed TGF-beta1 produced similar amounts of protein and grew more slowly in vitro than controls. The parent cell line and all transfected cells were growth inhibited (60-75%) by exogenous TGF-beta1. Orthotopic transplantation of the parent and the vector-only control cell lines resulted in primary tumours in the floor of the mouth in almost 100% (20/21) of athymic mice, with no evidence of bone resorption at the site of the primary tumour and pulmonary metastatic tumour deposits in some 40% (7/20) of these animals. The polygonal and spindle cells that overexpressed TGF-beta1 behaved similarly following orthotopic transplantation. A 96% (23/24) primary tumour take was evident following transplantation of cells that overexpressed TGF-beta1, with a significantly (P<0.02) higher number of animals showing bone resorption at the site of the primary tumour (35%; 8/23) compared to controls. By contrast, there was a significant (P<0.03) decrease in the number of animals with pulmonary metastases (4%; 1/23) following transplantation of TGF-beta1 overexpressing cells compared to controls. Overexpression of TGF-beta1 did not alter tumour cell differentiation in vivo. The results demonstrate that endogenous TGF-beta1 functions as a tumour suppressor in the rat-4NQO model of oral carcinogenesis without altering tumour cell morphology or differentiation but can also act to promote local bone resorption.
Subject(s)
Bone Resorption/physiopathology , Mouth Neoplasms/pathology , Transforming Growth Factor beta/physiology , Tumor Cells, Cultured/physiology , Animals , Cell Division/genetics , Cell Division/physiology , Cell Line, Transformed , Mice , Mice, Nude , Neoplasm Metastasis , Neoplasm Transplantation , Rats , Transfection/genetics , Transforming Growth Factor beta/genetics , Tumor Cells, Cultured/pathologyABSTRACT
This study examined the metastatic capacity of clonal populations of 4NQO-induced rat malignant oral keratinocytes following orthotopic transplantation to athymic mice. Polygonal and spindle cells formed well-differentiated squamous cell carcinomas (keratin positive and vimentin negative) and undifferentiated spindle cell tumours (keratin negative and vimentin positive), respectively, in almost 100% of animals at the site of inoculation (floor of mouth). Transplantation of 5x 10(6) cells of either cell type at high cell density resulted in approximately 50% of animals forming pulmonary metastases. By contrast, inoculation of 2x 10(6) differentiated polygonal cells resulted in the formation of significantly fewer pulmonary metastases than the undifferentiated spindle cells. A single well-differentiated clone of polygonal cells and 3 of 4 of the undifferentiated spindle cell lines produced comparable levels of TGF-beta1. One undifferentiated spindle cell line expressed significantly more TGF-beta1 and, following transplantation orthotopically, fewer animals formed pulmonary metastases despite the formation of primary tumours in almost all grafted animals, suggesting that TGF-beta1 can act as a tumour suppressor in this cell type. All cell lines produced comparable amounts of TGF-beta2. The clones of polygonal cells were markedly inhibited and the spindle cells were only partially inhibited by exogenous TGF-beta1. Both cell types expressed high-affinity TGF-beta cell surface receptors; the ratio of type I to type II TGF-beta receptors was 1.0:<3.0 in the spindle cells and 1.0:17.9 in the polygonal clone. The results suggest that differentiated rat malignant oral keratinocytes are less aggressive and have a decreased potential to metastasise than their undifferentiated spindle cell counterparts. This may be attributable, in part, to a change in TGF-beta receptor profile leading to the partial loss of response to exogenous TGF-beta1.
Subject(s)
Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/secondary , Carcinoma/pathology , Carcinoma/secondary , Keratinocytes/pathology , Lung Neoplasms/secondary , Mouth Neoplasms/pathology , 4-Nitroquinoline-1-oxide , Animals , Carcinoma/chemically induced , Carcinoma/metabolism , Carcinoma, Squamous Cell/chemically induced , Carcinoma, Squamous Cell/metabolism , Cell Differentiation , Cell Transplantation , Clone Cells , Keratinocytes/drug effects , Keratinocytes/metabolism , Lymphatic Metastasis , Male , Mice , Mice, Nude , Mouth Neoplasms/chemically induced , Mouth Neoplasms/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Transforming Growth Factor beta/biosynthesis , Transforming Growth Factor beta/pharmacology , Tumor Cells, CulturedABSTRACT
No dedicated clinicopathological database for thyroid cancer exists in Wales to provide information about the incidence, histology, treatment and outcome of this uncommon malignancy. We have used cancer registry data to examine the epidemiology of thyroid cancer in Wales between 1985 and 1996 and have searched the database for clinically relevant data about stage, treatment and survival. A total of 699 cases were identified in this 12-year period, with no significant differences in their distribution between the five health authorities. Further analysis revealed a very wide age range (8-93 years) with a predominance of females (F:M ratio 2.8:1) and survival strongly influenced by gender, age and histological type. There were insufficient data to stage these cancers and only limited data about the surgical procedures undertaken. There was no information on non-surgical treatments (radio-iodine, radiotherapy and chemotherapy) in the database. Cancer registry data is well able to sustain an analysis of the epidemiology of thyroid cancer but further work is necessary to improve the quality of clinically relevant information about stage and treatment that could be used for audit.
Subject(s)
Registries , Thyroid Neoplasms/epidemiology , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Child , Female , Humans , Incidence , Male , Middle Aged , Prognosis , Sex Distribution , Survival Analysis , Thyroid Neoplasms/mortality , Thyroid Neoplasms/pathology , Thyroid Neoplasms/therapy , Wales/epidemiologyABSTRACT
This study examined the expression of fibroblast growth factor receptor 2 (FGFR 2) splice variants, IIIb and IIIc, in normal and malignant human oral keratinocytes and in normal oral fibroblasts by RT-PCR using both exon-specific primers and primers common to both FGFR 2 isoforms. Fibroblasts expressed exclusively FGFR 2/IIIc whilst the normal and malignant keratinocytes co-expressed FGFR 2/IIIb and FGFR 2/IIIc. Well-differentiated keratinocytes expressed proportionally more FGFR 2/IIIb than IIIc whereas the poorly-differentiated cells expressed more FGFR 2/IIIc than IIIb. The normal and malignant keratinocytes, but not fibroblasts, expressed an additional amplification product, which consisted of both IIIb and IIIc of FGFR 2 joined by an extra base pair and with the intronic sequence removed. The results indicate that the expression of FGFR 2 isoforms reflects the degree of cellular differentiation in normal and malignant human oral keratinocytes and that receptor complexes of FGFR 2/IIIb and IIIc may regulate ligand-receptor interactions.